Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 5/20 | 0.58 |
| ▸ | CRBN | Q96SW2 | 5/20 | 0.58 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.40 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.40 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | SOS1 | Q07889 | 2/20 | 0.36 |
| ▸ | IKZF2 | Q9UKS7 | 6/20 | 0.35 |
| ▸ | CSF1R | P07333 | 1/20 | 0.34 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.33 |
| ▸ | CDK9 | P50750 | 1/20 | 0.33 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL23538592 | 0.99 | DDB1 (0.57) | DDB1CRBNTLR9TLR8TLR7 | |
| Trifluoroacetic Acid SCHEMBL29253681 | 0.95 | DDB1 (0.52) | DDB1CRBNTLR9TLR8TLR7 | |
| SCHEMBL30822466 | 0.89 | DDB1 (0.53) | DDB1CRBNTLR9TLR8TLR7 | |
| SCHEMBL25452601 | 0.89 | DDB1 (0.62) | DDB1CRBNTLR9TLR8TLR7 | |
| SCHEMBL23551327 | 0.88 | DDB1 (0.52) | DDB1CRBNTLR9TLR8TLR7 | |
| SCHEMBL23538829 | 0.87 | DDB1 (0.53) | DDB1CRBN | |
| SCHEMBL30258353 | 0.86 | DDB1 (0.55) | DDB1CRBNTLR9TLR8TLR7 | |
| SCHEMBL23538585 | 0.86 | DDB1 (0.52) | DDB1CRBNTLR9TLR8TLR7 | |
| SCHEMBL23538744 | 0.86 | DDB1 (0.52) | DDB1CRBNTLR9TLR8TLR7 | |
| SCHEMBL23538639 | 0.86 | DDB1 (0.52) | DDB1CRBNTLR9TLR8TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4735438-A2 | HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF KRAS | Merck Patent GmbH (DE) | 2026-05-06 | — | — | EP | disclosed |
| EP-4735452-A2 | HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF KRAS PROTEIN | Merck Patent GmbH (DE) | 2026-05-06 | — | — | EP | disclosed |
| EP-4722209-A1 | PROTAC COMPOUND TARGETING ESTROGEN RECEPTOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | Beijing Shenogen Pharma Group (CN) | 2026-04-08 | — | — | EP | disclosed |
| US-12559492-B2 | BRAF degraders | C4 THERAPEUTICS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-20260042782-A1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | C4 THERAPEUTICS, INC. (US) | 2026-02-12 | — | — | US | disclosed |
| EP-4681715-A2 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | C4 Therapeutics, Inc. (US) | 2026-01-21 | — | — | EP | disclosed |
| EP-4076450-B1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | C4 THERAPEUTICS INC (US) | 2025-12-10 | — | — | EP | disclosed |
| US-12486253-B2 | Therapeutics for the degradation of mutant BRAF | C4 THERAPEUTICS, INC. (US) | 2025-12-02 | — | — | US | disclosed |
| US-12486290-B2 | Isoindolinone and indazole compounds for the degradation of EGFR | C4 THERAPEUTICS, INC. (US) | 2025-12-02 | — | — | US | disclosed |
| US-20250270234-A1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | C4 THERAPEUTICS, INC. (US) | 2025-08-28 | — | — | US | disclosed |
| EP-4168407-A1 | BRAF DEGRADERS | C4 Therapeutics, Inc. (US) | 2023-04-26 | — | — | EP | disclosed |
| US-20230110648-A1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | C4 THERAPEUTICS, INC. (US) | 2023-04-13 | — | — | US | disclosed |
| US-20230110648-A1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | C4 THERAPEUTICS, INC. (US) | 2023-04-13 | — | — | US | disclosed |
| WO-2022261250-A1 | THERAPEUTICS FOR THE DEGRADATION OF MUTANT BRAF | C4 THERAPEUTICS, INC. (US) | 2022-12-15 | — | — | WO | disclosed |
| WO-2022261250-A1 | THERAPEUTICS FOR THE DEGRADATION OF MUTANT BRAF | C4 THERAPEUTICS, INC. (US) | 2022-12-15 | — | — | WO | disclosed |
| EP-4076450-A1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | C4 Therapeutics, Inc. (US) | 2022-10-26 | — | — | EP | disclosed |
| WO-2022032026-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF RET | C4 THERAPEUTICS, INC. (US) | 2022-02-10 | — | — | WO | disclosed |
| WO-2021255212-A1 | BRAF DEGRADERS | F. HOFFMANN-LA ROCHE AG (CH) | 2021-12-23 | — | — | WO | disclosed |
| WO-2021127561-A1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | C4 THERAPEUTICS, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
| WO-2021127561-A1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | C4 THERAPEUTICS, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12559492-B2 | BRAF degraders | BRAF, NRAS, HRAS | DDB1 425/4885CRBN 32/4885TLR9 3411/4885 |
| US-12486253-B2 | Therapeutics for the degradation of mutant BRAF | BRAF, NRAS, KRAS | DDB1 955/4885CRBN 194/4885TLR9 4353/4885 |
| US-12486290-B2 | Isoindolinone and indazole compounds for the degradation of EGFR | EGFR, ERBB2, ERBB3 | DDB1 576/4885CRBN 75/4885TLR9 4680/4885 |
| US-20230110648-A1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | EGFR, ERBB2, ERBB3 | DDB1 576/4885CRBN 75/4885TLR9 4680/4885 |
| US-20250270234-A1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | EGFR, ERBB2, ERBB3 | DDB1 576/4885CRBN 75/4885TLR9 4680/4885 |
| US-20260042782-A1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | EGFR, ERBB2, ERBB3 | DDB1 823/4885CRBN 25/4885TLR9 4794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.